Diabetes drug could be new weapon against heart attack damage
NCT ID NCT06174753
Summary
This study is testing whether a diabetes medication called dapagliflozin can help limit the amount of heart muscle damage in people who have just had a major heart attack (STEMI). The trial will enroll 256 patients who are undergoing emergency heart artery opening. Participants will receive either the drug or a placebo for 7 days, and heart scans will measure the size of the damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Ottawa Heart Institute
RECRUITINGOttawa, Ontario, K1Y 4W7, Canada
Contact
Conditions
Explore the condition pages connected to this study.